Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock par value $0.012 per share
-
Shares outstanding
-
41,009,592
-
Number of holders
-
46
-
Total 13F shares, excl. options
-
7,236,876
-
Shares change
-
-14,346
-
Total reported value, excl. options
-
$19,100,309
-
Value change
-
+$25,894
-
Number of buys
-
13
-
Number of sells
-
-15
-
Price
-
$2.64
Significant Holders of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) as of Q3 2025
53 filings reported holding ORMP - ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share as of Q3 2025.
ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) has 46 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7,236,876 shares
of 41,009,592 outstanding shares and own 17.65% of the company stock.
Largest 10 shareholders include BML Capital Management, LLC (3,167,231 shares), Murchinson Ltd. (1,751,559 shares), BOOTHBAY FUND MANAGEMENT, LLC (845,391 shares), Rathbones Group PLC (233,018 shares), BANK OF AMERICA CORP /DE/ (149,667 shares), RENAISSANCE TECHNOLOGIES LLC (148,900 shares), DIMENSIONAL FUND ADVISORS LP (147,487 shares), WELLS FARGO & COMPANY/MN (130,086 shares), CITADEL ADVISORS LLC (111,707 shares), and BlackRock, Inc. (109,733 shares).
This table shows the top 46 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.